Session Information

WCLC 2018

19th World Conference on Lung Cancer

Conference Program for the 19th World Conference on Lung Cancer in Toronto, Canada

Download PDF of the Abstract Book: Click Here.
Presentation Date(s):
- Sept 23 - 26, 2018
- Total Presentations: 2391
Register to Attend WCLC Return to WCLC 2018 Website Download Program (PDF) Book of Abstracts (PDF) Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Sunday
September 23 Sun
Sep 23 Monday
September 24 Mon
Sep 24 Tuesday
September 25 Tue
Sep 25 Wednesday
September 26 Wed
Sep 26

Filter Results:

Show Only CME Accredited Sessions

25724

+
MA02 - Improving Outcomes for Patients with Lung Cancer
- 10:30 - 12:00
- 9/24/2018
- Location: Room 201 BD
- Type: Mini Oral Abstract Session
- Track: Advanced NSCLC
- 25729
  
  +
  
  MA02.01 - ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events
  
  10:30 - 10:35 | Presenter: Terry L. Ng | Author(s): Derek E Smith, Rao Mushtaq, Tejas Patil, Anastasios Dimou, Shuo Yang, Qian Liu, Xuefei Li, Caicun Zhou, Flora Yan, I. Alex Bowman, Stephen V Liu, Robert C. Doebele, Dara L. Aisner, Shengxiang Ren, Ross Camidge
  Abstract
  
  Loading...
25921

+
P1.01 - Advanced NSCLC (Not CME Accredited Session)
- 16:45 - 18:00
- 9/24/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
- 26343
  
  +
  
  P1.01-111 - EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer
  
  16:45 - 18:00 | Presenter: Chao Zhao | Author(s): Xuefei Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Caicun Zhou
  Abstract
  
  Loading...
25904

+
MA15 - Colliding Approaches - EGFR and Immunotherapy
- 13:30 - 15:00
- 9/25/2018
- Location: Room 107
- Type: Mini Oral Abstract Session
- Track: Targeted Therapy
- 26035
  
  +
  
  MA15.09 - Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs
  
  14:30 - 14:35 | Presenter: Chunxia Su | Author(s): Tao Jiang, Jing Zhao, Xuefei Li, Caicun Zhou
  Abstract
  
  Loading...
- 26038
  
  +
  
  MA15.10 - Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
  
  14:35 - 14:40 | Presenter: Sha Zhao | Author(s): Tao Jiang, Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, Caicun Zhou
  Abstract
  
  Loading...
25952

+
P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session)
- 16:45 - 18:00
- 9/25/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
- 27255
  
  +
  
  P2.15-33 - Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens After Panel Testing by NGS?
  
  16:45 - 18:00 | Presenter: Chunxia Su | Author(s): Jing Zhao, Shen Jiqiao, Xuefei Li, Caicun Zhou
  Abstract
  
  Loading...
25954

+
P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session)
- 16:45 - 18:00
- 9/25/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
- 27323
  
  +
  
  P2.17-12 - Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression
  
  16:45 - 18:00 | Presenter: Xiaomei Gong | Author(s): Xuefei Li, Yaping Xu, Caicun Zhou
  Abstract
  
  Loading...
25958

+
P3.04 - Immunooncology (Not CME Accredited Session)
- 12:00 - 13:30
- 9/26/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
- 27531
  
  +
  
  P3.04-21 - Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer
  
  12:00 - 13:30 | Presenter: Sha Zhao | Author(s): Yijun Jia, Tao Jiang, Xuefei Li, Wei Li, Guanghui Gao, Chao Zhao, Yayi He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou
  Abstract
  
  Loading...
25918

+
MA26 - New Therapies and Emerging Data in ALK, EGFR and ROS1
- 13:30 - 15:00
- 9/26/2018
- Location: Room 201 BD
- Type: Mini Oral Abstract Session
- Track: Targeted Therapy
- 26206
  
  +
  
  MA26.05 - Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants
  
  14:00 - 14:05 | Presenter: Meng Qiao | Author(s): Chao Zhao, Xuefei Li, Tao Jiang, Fengying Wu, Xiaoxia Chen, Chunxia Su, Caicun Zhou
  Abstract
  
  Loading...
25919

+
MA27 - Novel Drugs and PDX Models
- 13:30 - 15:00
- 9/26/2018
- Location: Room 206 BD
- Type: Mini Oral Abstract Session
- Track: Targeted Therapy
- 26219
  
  +
  
  MA27.10 - EGFR-Targeted Therapy Alters the Tumor Microenvironment In EGFR-Driven Lung Tumors: Rationale for Combination Therapies
  
  14:35 - 14:40 | Presenter: Yijun Jia | Author(s): Tao Jiang, Xuefei Li, Chao Zhao, Caicun Zhou, Sha Zhao
  Abstract
  
  Loading...

Session Information

WCLC 2018

19th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

MA02 - Improving Outcomes for Patients with Lung Cancer

+

MA02.01 - ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events

+

P1.01 - Advanced NSCLC (Not CME Accredited Session)

+

P1.01-111 - EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer

+

MA15 - Colliding Approaches - EGFR and Immunotherapy

+

MA15.09 - Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs

+

MA15.10 - Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

+

P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session)

+

P2.15-33 - Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens After Panel Testing by NGS?

+

P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session)

+

P2.17-12 - Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression

+

P3.04 - Immunooncology (Not CME Accredited Session)

+

P3.04-21 - Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer

+

MA26 - New Therapies and Emerging Data in ALK, EGFR and ROS1

+

MA26.05 - Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants

+

MA27 - Novel Drugs and PDX Models

+

MA27.10 - EGFR-Targeted Therapy Alters the Tumor Microenvironment In EGFR-Driven Lung Tumors: Rationale for Combination Therapies

Stay Connected